Peking University International Hospital and BAHEAL MEDICAL Establish Real-world Study on Brain Metastases With ZAP-X Gyroscopic Radiosurgery Platform

Peking University International Hospital (PKUIH) successfully hosted the Academic Conference on the Frontiers of Stereotactic Radiosurgery (SRS) Technology and Clinical Advances in Brain Tumors. Nearly 30 experts from over a dozen top-tier domestic medical institutions, including PKUIH, Peking Union Medical College Hospital, Xuanwu Hospital Capital Medical University, and the First Medical Center of the PLA General Hospital, gathered to engage in-depth discussions on key topics including advancing high-quality, collaborative approaches to brain tumor diagnosis and treatment, as well as exploring international development trends in radiotherapy for brain metastases.

Participant group photo

Brain tumors occur when a neoplasm, or abnormal growth, forms into a mass within the skull. These growths are broadly divided into two main categories based on their behavior. Benign tumors are non-cancerous growths that grow slowly and typically do not invade nearby tissue; in contrast, malignant tumors are cancerous, aggressive, and life-threatening.

Malignant tumors are further classified into two types: gliomas, which originate from the supportive tissue of the brain itself, and brain metastases, which are cancer cells that have spread from the brain from another part of the body (such as the lung, breast, or skin). Brain metastases are a significant indicator of advanced cancer and present immense treatment challenges. In China, approximately 1.5 million new cases of brain metastases are diagnosed annually, posing a major challenge that clinical diagnosis and treatment urgently needs to address.

The ZAP-X Gyroscopic Radiosurgery Platform (hereinafter referred to as ZAP-X), provides radiotherapy for tumors and lesions in the brain, head, and neck. It has been launched in over 24 countries and regions globally with more than 5,000 clinical applications. It can deliver radiation from thousands of non-coplanar beam angles, precisely targeting the tumor while maximizing the protection of surrounding healthy tissue, offering significant advantages in brain tumor treatment.

As one of the first medical institutions in China to deploy ZAP-X, PKUIH, in collaboration with BAHEAL MEDICAL, established a Precision Radiotherapy Center and introduced ZAP-X to research the clinical potential of radiosurgery in brain tumor treatment. During the conference, both parties announced the official launch of a ZAP-X real-world study. By leveraging real-world data from ZAP-X clinical applications, the study aims to accelerate the validation of its value across various brain tumor subtypes, with the ultimate goal of providing longer and better-quality survival for brain tumor patients.

Launch ceremony at PKUIH

Dr. Liang Jun, Conference Chair, Party Secretary, and Executive Vice President of PKUIH, stated that brain tumor diagnosis and treatment are moving towards a new stage of multidisciplinary integration. He noted that the conference brought together expertise from multiple disciplines, including Oncology, Neurosurgery, and Radiotherapy, to jointly promote innovation and the clinical implementation of precision diagnostic and treatment technologies for brain tumors, thereby improving patient quality of life.

Speech by Dr. Liang Jun, Party Secretary and Executive Vice President of Peking University International Hospital

Mr. Fu Gang, Chairman of BAHEAL MEDICAL, emphasized the critical role of "industry-academia-research-medical" collaboration in facilitating the integration of innovative technologies into clinical practice. He stated that the company is committed to building the evidence-based medicine framework for ZAP-X in China, supporting the standardized application and promotion of precision radiotherapy technology, and comprehensively enhancing the nation's standards for brain tumor diagnosis and treatment.

Mr. Fu Gang, Chairman of BAHEAL MEDICAL, delivering a speech

Dr. Nie Shaoping, Vice President of PKUIH, and Dr. Zhao Yuanli, Director of the Neurosurgery Department, shared their perspectives on the hospital's teaching and research initiatives. They also discussed the advanced interdisciplinary cooperation and future development of Oncology and Neurosurgery, calling for the establishment of a standardized yet personalized comprehensive diagnosis and treatment system for brain metastases.

Dr. Nie Shaoping, Vice President of Peking University International Hospital, delivering a speech

Dr. Zhao Yuanli, Director of Neurosurgery at Peking University International Hospital, delivering a speech

During his keynote session, Dr. John R. Adler, a pioneer in the field of radiosurgery and Professor Emeritus of Neurosurgery and Radiation Oncology at Stanford University, systematically reviewed the development trajectory of radiosurgery technology. He proposed that precision is not merely a technical pursuit but the core element in enhancing treatment efficacy and patient outcomes.

Dr. John R. Adler delivering a speech

Dr. Li Xiaoyan, Deputy Director of the Cancer Center at Beijing Tiantan Hospital, Capital Medical University, highlighted the progress of medical treatments such as targeted therapy, immunotherapy, and novel chemotherapy drugs in managing brain metastases. She emphasized that multidisciplinary team (MDT) collaboration is a crucial strategy for prolonging patient survival.

Dr. Li Xiaoyan delivering a speech

Dr. Xu Lixin from the Neurosurgery Department (Gamma Knife Center) at Xuanwu Hospital, Capital Medical University, shared innovative practices and future perspectives on the role of neurosurgery in the multidisciplinary management of brain metastases. He introduced the goals and progress of the Chinese Intracranial Metastases Collaborative Group and called for the development of more comprehensive diagnostic and treatment standards and expert consensus.

Dr. Xu Lixin delivering a speech

Dr. Pan Longsheng from the First Medical Center of the PLA General Hospital shared practical experiences based on the clinical trial cases of ZAP-X at his institution, covering technical details and indication selection.

Dr. Pan Longsheng delivering a speech

The BAHEAL MEDICAL Brain Metastases Pioneering Program was officially launched during the conference. This program focuses on the significant domestic need for precision treatment of brain metastases and addresses key clinical pain points. It systematically promotes coordinated efforts across three dimensions: academic development, clinical research collaboration, and diagnosis/treatment service optimization. The goal is to form an integrated solution covering scientific research, clinical practice, and patient management, providing a practical pathway for building a precise and standardized diagnosis and treatment system for brain metastases in China.

Dr. Liang Jun delivered the concluding remarks, acknowledging the conference's success in promoting academic exchange and optimizing clinical protocols. He expressed his hope that the ZAP-X real-world study would serve as a catalyst to continuously deepen multi-center collaboration and clinical innovation in the brain tumor field, contributing to the high-quality development of China's healthcare sector.